TRANEXAMIC ACID IN DECREASING BLOOD LOSS DURING CESAREAN SECTIO
- Registration Number
- CTRI/2022/11/047026
- Lead Sponsor
- Dr Krishna Memakiya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1)Age > 18 year
2)Cesarean delivery, either before or during labor
3)Gestational age >= 34 weeks
4)Prenatal hemoglobin level in the week before the cesarean > 9 gm%
5)Signed informed consent
1)History of venous (deep vein thrombosis and/or pulmonary embolism) or arterial (angina pectoris,myocardial infarction, or stroke) thrombosis
2) History of epilepsy or seizure
3)Any known active cardiovascular, renal or liver disorders
4) Autoimmune disease
5) Sickle cell disease
6) Severe hemorrhagic disease
7) Abnormally invasive placenta (placenta accrete /increta/percreta)
8) Abruptio placentae and placenta previa
9) Eclampsia or HELLP (Hemolysis Elevated Liver Low Platelet) syndrome
10) In utero fetal death
11)Administration of low-molecular-weight heparin or antiplatelet agents in the week before delivery
12) Known hypersensitivity to tranexamic acid or concentrated hydrochloric acid
13) Cesarean delivery for the second twin or second/ third triplet(s) after vaginal birth of the first twin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the amount of blood loss from the end of placental delivery to the end of . two hours post partumTimepoint: end of two hours post partum
- Secondary Outcome Measures
Name Time Method the difference in haemoglobin % post operatively(24 hours after the cesarean section) among both groupTimepoint: the difference in haemoglobin % post operatively (24 hours after the cesarean section)among both group